Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients

Metabolism: Clinical and Experimental

Volumn 48, Issue 11, 1999, Pages 1437-1444

  Glueck, Charles J ^a,b   Lang, James E ^a   Tracy, Trent ^a   Sieve Smith, Luann ^a   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b Cholesterol Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY RISK; FEMALE; HUMAN; HYPERINSULINISM; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032698764     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90156-7     Document Type: Article

References (58)

1. Folsom AR, Szklo M, Stevens J, et al: A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 209:935-942, 1997
2. Lamarche B, Tchernof A, Mauriege P, et al: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 279:1955-1961, 1998
3. Burchfiel CM, Sharp DS, Curb JD, et al: Hyperinsulinemia and cardiovascular disease in elderly men: The Honolulu Heart Program. Arterioscler Thromb Vasc Biol 18:450-457, 1998
4. Edwards KL, Burchfiel CM, Sharp DS, et al: Factors of the insulin resistance syndrome in nondiabetic and diabetic elderly Japanese-American men. Am J Epidemiol 147:441-447, 1998
5. Despres JP, Lamarche B, Mauriege P, et al: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334:952-957, 1996
6. Gaudet D, Vohl MC, Perron P, et al: Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 97:871-877, 1998
7. Bonora E, Willeit J, Kicchl S, et al: Relationship between insulin and carotid atherosclerosis in the general population. The Bruneck Study. Stroke 28:1147-1152, 1997
8. Suzuki M, Shinozaki K, Kanazawa A, et al: Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 28:593-598, 1996
9. Donahue RP, Bean JA, Donahue RD, et al: Does insulin resistance unite the separate components of the insulin resistance syndrome? Evidence from the Miami Community Health Study. Arterioscler Thromb Vasc Biol 17:2413-2417, 1997
10. Bao W, Srinivasan SR, Berenson GS: Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults. The Bogalusa Heart Study. Circulation 93:54-59, 1996
11. Carantoni M, Zuliani G, Volpato S, et al: Relationships between fasting plasma insulin, anthropometrics, and metabolic parameters in a very old healthy population. Associazione Medica Sabin. Metabolism 47:535-540, 1998
12. Hughes K, Aw TC, Kuperan P, et al: Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health 51:394-399, 1997
13. Jeppesen J, Facchini FS, Reaven GM: Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant. J Intern Med 243:293-298, 1998
14. Edwards KL, Newman B, Mayer E, et al: Heritability of factors of the insulin resistance syndrome in women twins. Genet Epidemiol 14:241-253, 1997
15. Grundy SM: Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 81:18B-25B, 1998
16. Afonso LC, Edelson GW, Sowers JR: Metabolic abnormalities in hypertension. Curr Opin Nephrol Hypertens 6:219-223, 1997
17. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
18. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
19. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
20. UK Prospective Diabetes Study Group: UK Prospective Diabetes Study 24: Relative efficacy of sulfonylurea, insulin, and metformin therapy in newly diagnosed non-insulin dependent diabetes with primary diet failure followed for six years. Ann Intern Med 128:165-175, 1998
21. Glueck CJ, Lang JE: Lipoprotein metabolism in the elderly, in Abrams WB, Beers MH, Berkow RB (eds): The Merck Manual of Geriatrics. Rahway, NJ, Merck, 1995, pp 1023-1052
22. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
23. Gruppo R, Glueck CJ, McMahon RE, et al: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Pathophysiology of osteonecrosis of the jaw. J Lab Clin Med 127:481-489, 1996
24. Glueck CJ, Shaw P, Lang J, et al: Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75:132-136, 1995
25. Glueck CJ, Glueck HI, Tracy T, et al: Relationship between Lp(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer. Metabolism 42:236-246, 1993
26. Hughes JR, Davies JA: Anticardiolipin antibodies in clinical situations associated with a risk of thrombotic events. Thromb Res 89:101-106, 1998
27. Velazquez E, Mendoza SG, Wang P, et al: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism 46:454-457, 1997
28. Ferrannini E, Natali A, Bell P, et al: Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). I Clin Invest 100:1166-1173, 1997
29. Fernandez-Real JM, Casamitjana R, Ricart-Engel W: Leptin is involved in gender-related differences in insulin sensitivity. Clin Endocrinol (Oxf) 49:505-511, 1998
30. Falkner B, Hulman S, Kushner H: Gender differences in insulin-stimulated glucose utilization among African-Americans. Am J Hypertens 11:948-952, 1994
31. Snehalatha C, Ramachandran A, Satyavani K, et al: Computed axial tomographic scan measurement of abdominal fat distribution and its correlation with anthropometry and insulin secretion in healthy Asian Indians. Metabolism 46:1220-1224, 1997
32. Kennedy A, Gettys TW, Watson P, et al: The metabolic significance of leptin in humans: Gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 82:1293-1300, 1997
33. Snedecor BW, Cochran WG: Statistical Methods (ed 7). Ames, IA, Iowa State University Press, 1980
34. Lipid Research Clinics, Population Studies Data Book, vol 1. The Prevalence Study. National Institutes of Health Publication No. 80-1527, July 1980
35. Criqui MH, Golomb BA: Epidemiologic aspects of lipid abnormalities. Am J Med 105:488-575, 1998 (suppl)
36. Castelli WP: The new pathophysiology of coronary artery disease. Am J Cardiol 82:60T-65T, 1998
37. Hopkins PN, Hunt SC, Schreiner PJ, et al: Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease: Results from the NHLBI Family Heart Study. Atherosclerosis 141:333-345, 1998
38. Cubero GI, Reguero JJ, Batalla A, et al: Plasma lipids, HDL and apolipoproteins, and coronary heart disease in men less than 50 years old. A case-control study. Acta Cardiol 53:269-273, 1998
39. Cusi K, Consoli A, DeFronzo RA: Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067, 1996
40. Bavenholm P, de Faire U, Landou C, et al: Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 19:402-410, 1998
41. Glueck CJ, Rorick MH, Schmerler M, et al: Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 125:319-325, 1995
42. DeFronzo RA, Tobin JD, Andres R: The glucose clamp technique: A method for the quantification of beta cell sensitivity to glucose and of tissue sensitivity to insulin. Am J Physiol 237:E214-E223, 1979
43. Zavaroni I, Bonora E, Pagliara M, et al: Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance test. N Engl J Med 320:703-706, 1989
44. Fontbonne A, Charles MA, Thibult N, et al: Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15 year follow-up. Diabetologia 34:356-361, 1991
45. Haffner SM, Valdez RA, Hazuda HH, et al: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
46. Laakso M: How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959-965, 1993
47. Bonora E, Moghetti P, Zancanaro C, et al: Estimates of in vivo insulin action in man: Comparison of insulin tolerance tests and euglycemic and hyperglycemic glucose clamp studies. J Clin Endocrinol Metab 68:374-378, 1989
48. Saad MF, Anderson RI, Laws A, et al: A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43:1114-1121, 1994
49. Saad MF, Steil GM, Kades WW, et al: Differences between the tolbutamide-boosted and the insulin-modified minimal model protocols. Diabetes 46:1167-1171, 1997
50. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
51. Saad MF, Knowler WC, Pettitt DJ, et al: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500-1507, 1988
52. Bonora E, Kiechl S, Willeit J, et al: Prevalence of insulin resistance in metabolic disorders: The Bruneck Study. Diabetes 47:1643-1649, 1998
53. Reaven GM: Banting Lecture 1987: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
54. Howard G, O'Leary DH, Zaccaro D, et al: Insulin sensitivity and atherosclerosis. Circulation 93:1809-1817, 1996
55. Vaarala O, Manttari M, Manninen V, et al: Anticardiolipin antibodies and risk of MI in a prospective cohort of middle-aged men. Circulation 91:23-27, 1995
56. Wu R, Nityanand S, Berglund L, et al: Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict MI. Arterioscler Thromb Vasc Biol 17:3159-3163, 1997
57. Glueck CJ, Lang JE, Tracy T, et al: Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol 83:1490-1494, 1999
58. Folsom AR, Nieto FJ, McGovern PG, et al: Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 98:204-210, 1998